K W Pratz

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
    Keith W Pratz
    Department of Oncology and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland
    Clin Cancer Res 22:3894-902. 2016
  2. pmc A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
    Keith W Pratz
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
    Clin Cancer Res . 2016
  3. pmc A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
    K W Pratz
    Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 24:1437-44. 2010
  4. ncbi request reprint Optimizing the dose and schedule of KW-2449, FLT3/Aurora inhibitor, through analysis of in vivo target inhibition
    K W Pratz
    Johns Hopkins University, Baltimore, MD Johns Hopkins University, Baltimore, MD University of Texas M D Anderson Cancer Center, Houston, TX Cornell University, New York, NY Kyowa Pharmaceutical Inc, Princeton, NJ Kyowa Hakko Kogyo Ltd, Shizuoka, Japan
    J Clin Oncol 26:7069. 2008
  5. ncbi request reprint Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias
    K W Pratz
    Johns Hopkins University, Baltimore, MD
    J Clin Oncol 27:7065. 2009

Detail Information

Publications5

  1. pmc Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
    Keith W Pratz
    Department of Oncology and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland
    Clin Cancer Res 22:3894-902. 2016
    ..Inhibitors of PARP have shown activity in solid tumors with defects in homologous recombination (HR). This study was performed to assess MPN sensitivity to PARP inhibitors ex vivo..
  2. pmc A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
    Keith W Pratz
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
    Clin Cancer Res . 2016
    ..This study evaluated veliparib incorporation into leukemia induction therapy using a previously described topotecan/carboplatin backbone...
  3. pmc A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
    K W Pratz
    Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 24:1437-44. 2010
    ..Although sorafenib showed only modest clinical activity as a single agent in this heavily treated population, robust inhibition of FLT3 and ERK suggests that there may be a potential important role in combination therapies...
  4. ncbi request reprint Optimizing the dose and schedule of KW-2449, FLT3/Aurora inhibitor, through analysis of in vivo target inhibition
    K W Pratz
    Johns Hopkins University, Baltimore, MD Johns Hopkins University, Baltimore, MD University of Texas M D Anderson Cancer Center, Houston, TX Cornell University, New York, NY Kyowa Pharmaceutical Inc, Princeton, NJ Kyowa Hakko Kogyo Ltd, Shizuoka, Japan
    J Clin Oncol 26:7069. 2008
    ..We conducted correlative pharmacodynamic and pharmacokinetic studies in the context of a phase I trial in order to determine if adequate FLT3 inhibition could be achieved using a twice daily dosing schedule of KW-2449...
  5. ncbi request reprint Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias
    K W Pratz
    Johns Hopkins University, Baltimore, MD
    J Clin Oncol 27:7065. 2009
    ..7065 Background: Sorafenib is a multikinase inhibitor with activity against B-raf, VEGF, and FLT3. Based on preclinical activity in FLT3 mutant AML, sorafenib was studied in refractory acute leukemia...